These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 12866439)

  • 1. [Molecular quantitation of minimal residual disease in leukemia].
    Tamaki H; Ogawa H
    Nihon Naika Gakkai Zasshi; 2003 Jun; 92(6):956-62. PubMed ID: 12866439
    [No Abstract]   [Full Text] [Related]  

  • 2. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.
    Qin Y; Zhu H; Jiang B; Li J; Lu X; Li L; Ruan G; Liu Y; Chen S; Huang X
    Leuk Res; 2009 Mar; 33(3):384-90. PubMed ID: 18950857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of minimal residual disease (MRD) estimated by flow cytometry and by real-time quantitative PCR of Wilms tumor gene 1 (WT1) transcript expression in children with acute lymphoblastic leukemia.
    Chen JS; Hsiao CC; Sheen JM; Cheng CN
    Leuk Res; 2007 Oct; 31(10):1351-7. PubMed ID: 17445885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative analysis of PRAME for detection of minimal residual disease in leukemia.
    Matsushita M; Yamazaki R; Kawakami Y
    Methods Mol Med; 2004; 97():267-75. PubMed ID: 15064499
    [No Abstract]   [Full Text] [Related]  

  • 5. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
    Doubek M; Palasek I; Pospisil Z; Borsky M; Klabusay M; Brychtova Y; Jurcek T; Jeziskova I; Krejci M; Dvorakova D; Mayer J
    Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Application of WT1 transcript assay for allogeneic stem cell transplantation for acute leukemia].
    Ogawa H
    Rinsho Ketsueki; 2004 Jul; 45(7):501-8. PubMed ID: 15359908
    [No Abstract]   [Full Text] [Related]  

  • 7. WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia?
    Bader P; Niemeyer C; Weber G; Coliva T; Rossi V; Kreyenberg H; Gerecke A; Biondi A
    Eur J Haematol; 2004 Jul; 73(1):25-8. PubMed ID: 15182334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Minimal residual disease. Methodologies and clinical implications].
    Ortega M; Coll MD; Solé F; Caballín MR
    Sangre (Barc); 1999 Aug; 44(4):283-90. PubMed ID: 10589280
    [No Abstract]   [Full Text] [Related]  

  • 9. Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation.
    Uzunel M; Ringdén O
    Bone Marrow Transplant; 2004 Jan; 33(1):47-52. PubMed ID: 14704656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of WT1 expression in bone marrow vs peripheral blood samples of children with acute myeloid leukemia-impact on minimal residual disease detection.
    Kramarzova K; Boublikova L; Stary J; Trka J
    Leukemia; 2013 Apr; 27(5):1194-6. PubMed ID: 23047476
    [No Abstract]   [Full Text] [Related]  

  • 11. [Minimal residual disease in malignant diseases of the blood I. Background and pre-clinical validation].
    Hokland P; Nyvold CG; Stentoft J; Ommen HB; Ebbesen LH; Braendstrup K; Andersen BL; Mikkelsen LS; Ostergaard M
    Ugeskr Laeger; 2009 Jan; 171(4):229-31. PubMed ID: 19174037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of a new inspection diagnostic method: genetic screening of cancer].
    Sugiyama H
    Rinsho Byori; 2004 May; 52(5):426-9. PubMed ID: 15206129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of minimal residual disease using WT1 assay for patients with chronic myeloid leukemia who undergo allogeneic stem cell transplantation.
    Tamaki H; Ogawa H
    Bone Marrow Transplant; 2004 Oct; 34(7):653-4. PubMed ID: 15258561
    [No Abstract]   [Full Text] [Related]  

  • 14. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study.
    Østergaard M; Olesen LH; Hasle H; Kjeldsen E; Hokland P
    Br J Haematol; 2004 Jun; 125(5):590-600. PubMed ID: 15147374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
    Cilloni D; Renneville A; Hermitte F; Hills RK; Daly S; Jovanovic JV; Gottardi E; Fava M; Schnittger S; Weiss T; Izzo B; Nomdedeu J; van der Heijden A; van der Reijden BA; Jansen JH; van der Velden VH; Ommen H; Preudhomme C; Saglio G; Grimwade D
    J Clin Oncol; 2009 Nov; 27(31):5195-201. PubMed ID: 19752335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Genetic diagnosis of leukemia: diagnosis of relapse and complete remission, and prediction of leukemia onset].
    Sugiyama H
    Rinsho Byori; 2000 Feb; 48(2):155-61. PubMed ID: 10804819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of minimal residual disease in acute promyelocytic leukemia.
    Lengfelder E; Reiter A; Saussele S; Weisser A; Hehlmann R
    Ann Hematol; 2004; 83 Suppl 1():S79-80. PubMed ID: 15124684
    [No Abstract]   [Full Text] [Related]  

  • 18. Follow-up of minimal residual disease in acute childhood lymphoblastic leukemia by WT1 gene expression in the peripheral blood: the Hungarian experience.
    Magyarosy E; Varga N; Timár J; Rásó E
    Pediatr Hematol Oncol; 2003; 20(1):65-74. PubMed ID: 12687755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The significance of detecting WT1 expression in childhood acute leukemias.
    Hu SY; Gu WY; Chen ZX; Wang XL; Cen JN; He HL; Chai YH; Chen CS
    Pediatr Hematol Oncol; 2010 Nov; 27(8):581-91. PubMed ID: 20863155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful donor leukocyte transfusion at molecular relapse for a patient with acute myeloid leukemia who was treated with allogenic bone marrow transplantation: importance of the monitoring of minimal residual disease by WT1 assay.
    Ogawa H; Tsuboi A; Oji Y; Tamaki H; Soma T; Inoue K; Sugiyama H
    Bone Marrow Transplant; 1998 Mar; 21(5):525-7. PubMed ID: 9535047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.